Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burdet

Showing results (391-400 of 398) with videos related to

Pageof 40
Sort By:
You have reached the last page of results.This site can display upto 398 results.
Life (Basel, Switzerland)|February 24, 2024
A Federated Database for Obesity Research: An IMI-SOPHIA StudyCarl Delfin, Iulian Dragan, Dmitry Kuznetsov, et al.
The Journal of Allergy and Clinical Immunology|August 26, 2023
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypesLaura Polivka, Marine Madrange, Cristina Bulai-Livideanu, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Nature Communications|May 3, 2023
Identification of biomarkers for glycaemic deterioration in type 2 diabetesRoderick C Slieker, Louise A Donnelly, Elina Akalestou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Science Immunology|August 20, 2021
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19Takaki Asano, Bertrand Boisson, Fanny Onodi, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 40

Showing results (391-400 of 398) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 398 results.
Life (Basel, Switzerland)|February 24, 2024
A Federated Database for Obesity Research: An IMI-SOPHIA StudyCarl Delfin, Iulian Dragan, Dmitry Kuznetsov, et al.
The Journal of Allergy and Clinical Immunology|August 26, 2023
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypesLaura Polivka, Marine Madrange, Cristina Bulai-Livideanu, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Nature Communications|May 3, 2023
Identification of biomarkers for glycaemic deterioration in type 2 diabetesRoderick C Slieker, Louise A Donnelly, Elina Akalestou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Science Immunology|August 20, 2021
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19Takaki Asano, Bertrand Boisson, Fanny Onodi, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 40